How the Experts Treat Hematologic Malignancies: Physician Track

Given the increasing frequency of Hematologic Malignancy, especially in an aging population, as well as the complexities of individual clinic presentation, there is a need to provide an opportunity for Oncologists, Hematologists and Oncology Nurses to engage in a thoughtful examination and discussion with experts in various hematologic cancers. There is also emerging data about the biology of these cancers that underlies modern optimal management of patients with these disorders. The expansion of patient care options in nearly all of these disorders make decision making more complex. This two and a half day symposium has been designed by experts in the field of hematologic malignancies and affords the conferee specialized educational tracks for both physicians and nurses providing the opportunity to learn about the most recent advances in the treatment of bone marrow transplant, multiple myeloma, lymphoma and leukemia. Updates on improved curative and palliative treatments and evolving molecular and immunologically-based system therapies, as well as important, completed or ongoing clinical trials, will be profiled and discussed.

EVENT DETAILS AND REGISTRATION

Date:March 15, 2017

Time: 05:00 PM - 05:00 PM (PT)

Location:Mandarin Oriental , 3752 Las Vegas Blvd South, Las Vegas NV 89109

Event Is:At the end of this continuing medical education activity, participants should be able to:

  • Review the role and timing of hematologic cell transplant in the management of younger and older patients
  • Provide an update of new molecular and immunological treatments being developed for these diseases
  • Discuss the rationale for new targeted diagnostic therapeutic strategies for lymphoma, myeloma and leukemia
  • Summarize the evolving therapeutic strategies in the treatment of hematologic malignancies
  • Integrate best practices for prevention, detection and management of side effects related to current therapies

ADDITIONAL DETAILS:

Objectives:

At the end of this continuing medical education activity, participants should be able to:
  • Review the role and timing of hematologic cell transplant in the management of younger and older patients
  • Provide an update of new molecular and immunological treatments being developed for these diseases
  • Discuss the rationale for new targeted diagnostic therapeutic strategies for lymphoma, myeloma and leukemia
  • Summarize the evolving therapeutic strategies in the treatment of hematologic malignancies
  • Integrate best practices for prevention, detection and management of side effects related to current therapies

Who should attend:

This educational program is directed towards hematologists, oncologists, pathologists, radiation oncologists, palliative care staff, oncologic nurses and other allied health care team members interested in the treatment of patients with cancer

CME credits:ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 16.25 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The following credit type(s) are being offered for this course: •  AMA PRA Category1™  (16.25) The following may apply AMA Category 1 Credit(s)™ for license renewal: Registered Nurses: Nurses may report up to 16.25 credit hour(s) toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number. Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA Category 1 CreditTM

R.S.V.P.: https://cme.cityofhope.org/register.html?pid=7533

Web Link:https://cme.cityofhope.org/register.html?pid=7533